Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Pluri Inc. Common Stock

PLUR

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.946 – $1.06
Volume 24,484
Market cap $15M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$14.95M
Price / earnings
—
Price / book
-0.73×
Price / sales
10.25×
EV / sales
26.74×
EV / EBITDA
-1.18×

Profitability

Earnings per share
-$1.97
Return on assets
-113.77%
Return on equity
137.64%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.34×
Current ratio
0.27×
Quick ratio
0.27×
Cash ratio
0.11×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.23M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PLUR, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$759K$335K$167K$198K$316K$398K$427K$185K
Cost of revenue$339K$139K$111K$112K$201K$191K$291K$74K
Gross profit$420K$196K$56K$86K$115K$207K$136K$111K
Selling, general and administrative$2.32M$2.37M$2.63M$2.77M$2.53M$2.83M$2.49M$2.14M
Research and development$2.83M$3.42M$3.98M$3.95M$3.96M$4.21M$3.24M$3.17M
Total operating expenses$15.99M$5.27M$6.59M$6.59M$6.47M$7.03M$5.54M$5.07M
Operating income-$15.57M-$5.07M-$6.54M-$6.51M-$6.35M-$6.83M-$5.4M-$4.96M
Interest expense-$226K-$235K-$237K-$231K-$229K-$233K-$212K-$211K
Income before taxes-$15.38M-$6.19M-$6.18M-$6.88M-$6.14M-$7.77M-$6.34M-$3.11M
Income taxes$12K-$1K-$8K-$8K-$8K-$5K$0$0
Net income-$15.39M-$6.19M-$6.17M-$6.87M-$6.13M-$7.77M-$6.34M-$3.11M
Net income attributable to common shareholders-$10.39M-$5.88M-$5.55M-$6.54M-$5.85M-$7.6M-$6.15M-$2.96M
EBITDA-$15.44M-$4.95M-$6.41M-$6.38M-$6.22M-$6.72M-$5.33M-$4.89M
Basic earnings per share-$0.85-$0.55-$0.55-$0.71-$0.65-$0.98-$0.94-$0.53
Diluted earnings per share-$0.85-$0.55-$0.55-$0.71-$0.65-$0.98-$0.94-$0.53

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

DarioHealth Announces CFO Transition

DarioHealth Corp. announced that its Chief Financial Officer, Zvi Ben-David, will retire on May 15, 2025. The company has appointed Chen Franco-Yehuda as the new CFO, Treasurer, and Secretary, effective upon Ben-David's retirement.

Investing.com

Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com

Pluri Inc., a biotechnology firm, is facing the possibility of being delisted from the Nasdaq Capital Market due to failing to meet the minimum stockholders' equity requirement. The company has submitted a compliance plan and has been granted an extension until November 2024 to regain compliance.

GlobeNewswire Inc.

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

HAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced strategic investments in Pluri’s subsidiary, Ever After Foods Ltd. (“Ever After Foods”), which offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. Ever After Foods is Pluri’s majority-owned joint venture with Israeli food giant Tnuva Food-Tech Incubator (2019), L.P. (“Tnuva”), and has exclusive licensing rights to use Pluri’s technology and intellectual property to develop, manufacture and commercialize cultivated meat. The $10 million funding round will propel Ever After Foods’ cost-advantageous and scalable technology platform, positioning it as a leading technology enabler.

GlobeNewswire Inc.

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract

HAIFA, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023. During the 12 months from July 1, 2024 through June 30, 2025, the NIAID will provide $1.4 million for the Company to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 1, 20241-for-8reverse split
Jul 25, 20191-for-10reverse split